News

The Phase I study is being conducted using single and multiple oral doses with the objective of assessing safety and bioavailability of SUVN-502 in 67 healthy human beings.

Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Lipitor and Caduet in the US effective November 30, 2011. Caduet is

The program, which aims to protect against the two types of human papillomavirus (HPV) that are responsible for approximately 70% of cervical cancers, will start in September 2008

MitoSciences is offering two new solutions to researchers with the release of the MitoProfile Biogenesis kits. The MS631 MitoProfile Biogenesis Dipstick Kit is designed for point-of-care testing, and

The first study, performed in the US, is evaluating MVA-BN-HER2 treatment following chemotherapy and Herceptin treatment. In the second study, performed in Serbia and Poland, MVA-BN-HER2 is being

The studies evaluated the tissue distribution and pharmacokinetics of indium-111-edotreotide in two animal models. One study included in vitro studies and evaluated another potential imaging surrogate, indium-111-pentetreotide (Octreotide).

Under the terms of the collaboration, Kyowa Hakko will pay Alnylam $15 million in an upfront cash payment and up to an additional $78 million in development and

AcnEase is a proprietary herbal formula based on principles of traditional Chinese medicine and a modern herbaceutical science that is used for improving conditions associated with acne and

With the FDA CLIA waiver, non-laboratory trained physicians and other health care professionals in any health care facility with a Clinical Laboratory Improvement Amendments (CLIA) certificate of waiver